Lebrikizumab Side Effects
Medically reviewed by Drugs.com. Last updated on Nov 10, 2024.
Applies to lebrikizumab: subcutaneous solution.
Important warnings
This medicine can cause some serious health issues
Use only as directed.
Tell your doctor if you use other medicines or have other medical conditions or allergies.
Get emergency medical help if you have signs of an allergic reaction: hives, difficult breathing, swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have:
-
eye pain, or changes in your vision such as blurred vision;
-
skin rash; or
-
stomach cramps.
Common side effects may include:
-
pain, bruising, swelling, or irritation where the medicine was injected;
-
redness, swelling, itching or inflammation of your eyes or eyelids, or
-
skin sores or blisters, itching, tingling, burning pain, rash on your face or torso.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects.
For healthcare professionals
Applies to lebrikizumab: subcutaneous solution.
Dermatologic adverse events
- Uncommon (up to 1%): Herpes zoster[Ref]
Hematologic
- Uncommon (0.1% to 1%): Eosinophilia[Ref]
Local
- Common (1% to 10%): Injection site reaction[Ref]
Ocular
- Common (1% to 10%): Conjunctivitis
- Uncommon (0.1% to 1%): Keratitis[Ref]
References
1. (2024) "Product Information. Ebglyss Pre-filled Pen (lebrikizumab)." Eli Lilly Canada Inc
More about lebrikizumab
- Check interactions
- Compare alternatives
- Reviews (2)
- Dosage information
- During pregnancy
- Drug class: interleukin inhibitors
- Breastfeeding
- En español
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Further information
Lebrikizumab side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.